Middletown, DE -- (SBWIRE) -- 10/04/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: Orexigen Therapeutics, Inc.(NASDAQ:OREX), Tower Group International, Ltd.(NASDAQ:TWGP), XOMA Corp(NASDAQ:XOMA), Tellabs, Inc.(NASDAQ:TLAB)
Orexigen Therapeutics, Inc.(NASDAQ:OREX) was a volume gainer of 2.42 million shares and the average volume of the stock remained 1.02 million shares. The stock opened the session at $6.44 and finished at the end of the day at $6.39 and the stock escalated +5.45% .The market capitalizations of the stock remained 632.44 million. The half-yearly trend of the stock remained positive +8.31%. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
For How Long OREX will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Tower Group International, Ltd.(NASDAQ:TWGP) exchanged 2.36 million shares and the average volume remained 2.58 million shares. The stock closed the session at $7.78 with the drop of -1.77%. Tracking three months and 6 months trends, the stock was at of -62.70% and -56.97%, respectively.
Why Should Investors Buy TWGP After the Recent Fall? Just Go Here and Find Out
XOMA Corp(NASDAQ:XOMA) decreased -3.33% and its closing price was $5.23. The volume of the stock was 2.36 million shares and the average volume remained 1.06 million shares. Yesterday, the stock traded amid the day price range of $5.13 - $5.54. The market capitalization of the stock remained 473.92 million. The beta of the stock remained 2.41. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta).
Will XOMA Get Buyers Even After The Recent Rally? Find Out Here
Tellabs, Inc.(NASDAQ:TLAB) exchanged 2.35 million shares in the previous trading session, and its average trading remained 2.07 million shares. TLAB dropped -2.34% and it closed the trading at $2.30. The market capitalization of the stock remained 816.23 million. YTD trend of the stock was negative -1.71%. Tellabs, Inc. is engaged in designing and marketing equipment and services to communications-services providers worldwide. The company operates in four segments: optical, data, access and services. Its products and services, in combination with its Tellabs 8000 Intelligent Network Manager, enables its customers to deliver wireless and wireline voice.
Has TLAB Found The Bottom and Ready To Move Up? Find Out Here
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)